This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
mg kg | 1595 |
clinical signs | 1368 |
control group | 839 |
mean age | 678 |
risk factors | 603 |
united states | 579 |
side effects | 566 |
clinical trials | 508 |
bone marrow | 499 |
two groups | 499 |
may also | 485 |
significantly higher | 476 |
intensive care | 471 |
breast cancer | 463 |
years old | 456 |
one patient | 448 |
statistically significant | 443 |
abdominal pain | 443 |
differential diagnosis | 437 |
significant difference | 434 |
mental health | 425 |
weight loss | 412 |
aft er | 401 |
chronic hepatitis | 400 |
may occur | 391 |
acute respiratory | 377 |
blood pressure | 377 |
patients treated | 368 |
significant differences | 366 |
clinical trial | 364 |
minimally invasive | 360 |
mg dl | 357 |
hospital stay | 357 |
cancer patients | 353 |
physical examination | 348 |
infectious diseases | 348 |
cell lines | 332 |
lymph nodes | 327 |
case report | 323 |
two patients | 320 |
outcome measures | 320 |
gene expression | 319 |
design method | 318 |
ct scan | 317 |
retrospective study | 316 |
health care | 315 |
renal failure | 308 |
controlled trial | 305 |
clinical practice | 303 |
present study | 299 |
treatment group | 299 |
adverse events | 298 |
mortality rate | 298 |
systematic review | 297 |
median age | 296 |
respiratory tract | 296 |
main outcome | 295 |
adverse effects | 295 |
blood flow | 294 |
trauma patients | 289 |
increased risk | 289 |
high risk | 286 |
critically ill | 286 |
allergic rhinitis | 285 |
gastrointestinal tract | 283 |
intravenous immunoglobulin | 283 |
signifi cant | 275 |
specific ige | 274 |
ng ml | 273 |
respiratory distress | 271 |
mechanical ventilation | 269 |
oxidative stress | 266 |
intravenous drip | 266 |
prostate cancer | 266 |
soft tissue | 262 |
lymph node | 261 |
patients underwent | 257 |
respiratory syndrome | 256 |
care unit | 256 |
please specify | 254 |
abstract type | 254 |
small intestine | 252 |
important role | 251 |
liver disease | 251 |
activated charcoal | 249 |
stem cell | 249 |
heart failure | 249 |
pregnant women | 247 |
may result | 247 |
surgical treatment | 247 |
computed tomography | 242 |
old male | 242 |
emergency department | 240 |
urinary tract | 240 |
patients undergoing | 237 |
year old | 232 |
heart rate | 232 |
body weight | 231 |
mg ml | 230 |
least one | 230 |
fi rst | 229 |
risk factor | 229 |
hbv dna | 228 |
blood loss | 228 |
ml kg | 228 |
severe acute | 228 |
combination therapy | 227 |
cell line | 225 |
peripheral blood | 225 |
nervous system | 225 |
novel coronavirus | 225 |
septic shock | 224 |
patients received | 224 |
antibiotic therapy | 223 |
may cause | 222 |
performed using | 221 |
commonly used | 221 |
university hospital | 221 |
significantly lower | 217 |
blood samples | 211 |
patients receiving | 210 |
results showed | 209 |
coronavirus disease | 209 |
pediatric patients | 208 |
three patients | 207 |
immune response | 205 |
laparoscopic approach | 205 |
public health | 205 |
rheumatoid arthritis | 203 |
supportive care | 202 |
renal function | 202 |
lung cancer | 198 |
long term | 198 |
spinal cord | 197 |
prospective study | 196 |
cohort study | 195 |
respiratory failure | 194 |
pg ml | 193 |
learning objectives | 192 |
foreign bodies | 191 |
hepatocellular carcinoma | 191 |
sickle cell | 191 |
ill patients | 190 |
body mass | 189 |
foreign body | 189 |
old female | 188 |
abdominal wall | 187 |
diabetes mellitus | 187 |
nitric oxide | 187 |
colorectal cancer | 186 |
randomized controlled | 186 |
per day | 184 |
small intestinal | 183 |
monoclonal antibody | 182 |
immune system | 182 |
small bowel | 182 |
may lead | 182 |
operative time | 181 |
statistical analysis | 181 |
every hours | 180 |
flow cytometry | 177 |
widely used | 176 |
otitis media | 174 |
results suggest | 174 |
kg day | 174 |
laparoscopic surgery | 174 |
surgical intervention | 173 |
patients admitted | 173 |
blood cell | 173 |
primary care | 172 |
among patients | 172 |
one case | 172 |
doc id | 171 |
cancer cells | 171 |
cord uid | 171 |
monoclonal antibodies | 170 |
inflammatory response | 167 |
common cause | 167 |
endothelial cells | 167 |
case reports | 167 |
four patients | 165 |
stem cells | 165 |
kg iv | 165 |
growth factor | 165 |
significantly increased | 165 |
pleural effusion | 164 |
clinical findings | 164 |
average age | 163 |
cardiac output | 163 |
epithelial cells | 163 |
adult patients | 161 |
severe cases | 161 |
logistic regression | 161 |
virus infection | 161 |
treatment options | 161 |
severe covid | 160 |
study group | 160 |
postoperative day | 160 |
postoperative complications | 160 |
health services | 159 |
lopinavir ritonavir | 159 |
food allergy | 159 |
one study | 157 |
case series | 157 |
clinical symptoms | 156 |
red blood | 156 |
overall survival | 156 |
many cases | 155 |
study period | 154 |
patients without | 154 |
liver failure | 153 |
significant increase | 153 |
research abstract | 152 |
elderly patients | 152 |
central nervous | 152 |
type i | 152 |
bile duct | 152 |
mast cell | 152 |
abstract background | 152 |
western blot | 152 |
first trimester | 151 |
gastric cancer | 151 |
cell proliferation | 151 |
skin prick | 151 |
one year | 150 |
medical records | 150 |
two cases | 149 |
effective treatment | 148 |
cd cd | 148 |
states background | 148 |
th ere | 147 |
five patients | 147 |
antibiotic treatment | 146 |
platelet count | 146 |
lung disease | 146 |
cell carcinoma | 145 |
developing countries | 145 |
mg day | 143 |
antimicrobial drugs | 143 |
may require | 143 |
magnetic resonance | 143 |
significantly different | 143 |
whole blood | 142 |
identifi ed | 142 |
within days | 141 |
bacterial infection | 141 |
last years | 140 |
acquired pneumonia | 140 |
amino acid | 139 |
treatment locations | 139 |
cell death | 139 |
may help | 137 |
organ failure | 137 |
signifi cantly | 137 |
pilot study | 136 |
surgical procedures | 136 |
included patients | 136 |
clinical studies | 135 |
heart disease | 135 |
clinical features | 135 |
radiation therapy | 135 |
old woman | 135 |
group i | 134 |
significantly reduced | 134 |
rectal cancer | 134 |
distress syndrome | 133 |
viral load | 133 |
old man | 133 |
also may | 132 |
well tolerated | 132 |
observational study | 132 |
cell disease | 131 |
molecular weight | 131 |
definitive diagnosis | 131 |
inclusion criteria | 131 |
escherichia coli | 130 |
even though | 130 |
upper respiratory | 130 |
may include | 130 |
lung injury | 130 |
amino acids | 130 |
pulmonary disease | 129 |
general anesthesia | 129 |
tract infections | 129 |
commercially available | 129 |
higher risk | 128 |
young children | 128 |
recent years | 128 |
determine whether | 128 |
clinical outcomes | 127 |
colon cancer | 127 |
within hours | 127 |
pulmonary artery | 127 |
treatment effects | 127 |
liver function | 126 |
convalescent plasma | 126 |
syndrome coronavirus | 126 |
viral infections | 125 |
treated patients | 125 |
consecutive patients | 125 |
severe asthma | 125 |
will also | 125 |
pulmonary edema | 123 |
chronic pain | 123 |
copies ml | 123 |
survival rate | 123 |
smooth muscle | 123 |
significantly decreased | 122 |
blood cells | 122 |
intestinal obstruction | 122 |
chronic cough | 121 |
informed consent | 121 |
hospitalized patients | 121 |
recent studies | 121 |
liver biopsy | 121 |
patient care | 121 |
acute appendicitis | 121 |
world health | 121 |
twice daily | 121 |
differential diagnoses | 120 |
bowel disease | 120 |
clinical course | 119 |
analysis showed | 119 |
cell cycle | 119 |
medical treatment | 119 |
blood glucose | 119 |
blood transfusion | 119 |
tract infection | 119 |
imaging techniques | 118 |
atopic dermatitis | 118 |
regression analysis | 118 |
conservative treatment | 118 |
lung function | 118 |
ml min | 118 |
middle ear | 118 |
drug therapy | 118 |
th day | 118 |
clinical presentation | 117 |
myocardial infarction | 117 |
inflammatory bowel | 117 |
serum levels | 117 |
medical history | 116 |
somatic dysfunction | 116 |
three groups | 116 |
pet ct | 116 |
clinical characteristics | 116 |
surgical resection | 115 |
abdominal cavity | 115 |
mr imaging | 115 |
data suggest | 115 |
six patients | 115 |
dna damage | 115 |
treatment option | 115 |
large intestine | 115 |
mass index | 114 |
two different | 114 |
viral infection | 114 |
clinical improvement | 113 |
middle east | 113 |
general surgery | 113 |
lg ml | 113 |
hernia repair | 113 |
chart review | 113 |
aspiration pneumonia | 113 |
staphylococcus aureus | 113 |
age years | 112 |
medical center | 112 |
research complications | 112 |
gold standard | 112 |
hereditary angioedema | 112 |
early diagnosis | 112 |
high dose | 111 |
underlying disease | 110 |
liver cirrhosis | 110 |
infectious disease | 110 |
cell count | 110 |
iu ml | 110 |
free survival | 110 |
acute bronchitis | 110 |
patients showed | 110 |
substance use | 110 |
see chapter | 110 |
retrospective analysis | 110 |
operation time | 110 |
arterial blood | 109 |
liver injury | 109 |
patients may | 109 |
one may | 109 |
postoperative period | 109 |
standard care | 108 |
coronary artery | 108 |
first time | 108 |
type ii | 108 |
protein expression | 108 |
clinical pharmacy | 107 |
health organization | 107 |
imaging modalities | 107 |
fluid therapy | 107 |
seven patients | 106 |
polymerase chain | 106 |
white blood | 106 |
cell transplantation | 106 |
body temperature | 106 |
infected patients | 106 |
mrna expression | 106 |
chain reaction | 105 |
fatty acid | 105 |
statistical significance | 105 |
blood count | 105 |
family history | 105 |
red cell | 105 |
drinking water | 105 |
time pcr | 104 |
factors associated | 104 |
fatty acids | 104 |
wide range | 104 |
healthy controls | 104 |
grass pollen | 104 |
treatment response | 104 |
squamous cell | 104 |
retinal vein | 104 |
multivariate analysis | 104 |
gastric bypass | 104 |
infl uenza | 104 |
drug interactions | 103 |
mass spectrometry | 103 |
bacterial infections | 103 |
descriptive abstract | 103 |
insulin resistance | 103 |
treatment effect | 103 |
acute renal | 103 |
hemolytic anemia | 102 |
antiviral activity | 102 |
cancer cell | 102 |
measured using | 102 |
oral administration | 102 |
predictive value | 102 |
study showed | 102 |
analyzed using | 101 |
affected animals | 101 |
decision making | 101 |
randomized clinical | 101 |
significant improvement | 101 |
necrosis factor | 101 |
expression levels | 101 |
may provide | 101 |
cell viability | 101 |
many patients | 101 |
connective tissue | 100 |
surgical procedure | 100 |
treatment may | 100 |
type diabetes | 100 |
may contribute | 100 |
metabolic acidosis | 100 |
respiratory infections | 99 |
eight patients | 99 |
significant decrease | 99 |
poor prognosis | 99 |
preliminary results | 99 |
medication reconciliation | 99 |
necropsy findings | 99 |
analysis revealed | 99 |
mm hg | 99 |
several studies | 99 |
learning curve | 99 |
controlled trials | 99 |
wound healing | 98 |
initial treatment | 98 |
reactive protein | 98 |
immunodeficiency virus | 98 |
mortality rates | 98 |
clinical manifestations | 98 |
total ige | 97 |
per patient | 97 |
large number | 97 |
underlying cause | 97 |
respiratory syncytial | 97 |
may develop | 97 |
adverse reactions | 96 |
machine learning | 96 |
hearing loss | 96 |
small cell | 96 |
complication rate | 96 |
oral cavity | 95 |
selected patients | 95 |
clinical pharmacist | 95 |
phase ii | 95 |
clinically relevant | 95 |
critical care | 95 |
emergency surgery | 95 |
single dose | 95 |
tumor necrosis | 95 |
metastatic disease | 95 |
current study | 95 |
pulmonary hypertension | 95 |
vein occlusion | 95 |
converting enzyme | 95 |
east respiratory | 95 |
adrenal gland | 95 |
blood gas | 94 |
candidate treatment | 94 |
hospital admission | 94 |
inh concentrate | 94 |
congestive heart | 94 |
clinical data | 94 |
multiple myeloma | 94 |
eff ects | 94 |
peritoneal fluid | 94 |
randomized trial | 94 |
inh deficiency | 93 |
abdominal trauma | 93 |
less common | 93 |
respiratory disease | 93 |
one week | 93 |
cardiac surgery | 93 |
results indicate | 92 |
study aimed | 92 |
airway obstruction | 92 |
imaging findings | 92 |
human immunodeficiency | 92 |
surgical technique | 92 |
patients died | 92 |
may become | 92 |
allergic patients | 92 |
group ii | 92 |
study included | 92 |
tumor cells | 92 |
resonance imaging | 92 |
multiple sclerosis | 92 |
syncytial virus | 92 |
laparoscopic cholecystectomy | 91 |
mucous membranes | 91 |
respiratory rate | 91 |
cell tumors | 91 |
intravenous fluids | 91 |
multiple organ | 90 |
six months | 90 |
immune responses | 90 |
per year | 90 |
control groups | 90 |
lupus erythematosus | 90 |
term follow | 90 |
literature review | 90 |
house dust | 90 |
kg po | 89 |
patients aged | 89 |
folic acid | 89 |
year period | 89 |
become familiar | 89 |
left ventricular | 89 |
complete blood | 89 |
liver transplantation | 89 |
replacement therapy | 88 |
may play | 88 |
plasma concentrations | 88 |
cytokine storm | 88 |
orogastric lavage | 88 |
trauma center | 88 |
hematopoietic stem | 88 |
significant reduction | 88 |
patient presented | 88 |
treatment location | 88 |
disease may | 87 |
test results | 87 |
mg twice | 87 |
allergic reactions | 87 |
success rate | 87 |
laboratory findings | 87 |
ebola virus | 87 |
two years | 87 |
patients presented | 87 |
total protein | 87 |
different types | 87 |
patients diagnosed | 87 |
early stage | 87 |
mean follow | 86 |
pulmonary function | 86 |
causative microorganisms | 86 |
antimicrobial drug | 86 |
patient underwent | 86 |
disease progression | 86 |
see table | 86 |
emergency room | 86 |
general population | 86 |
animal models | 85 |
acute pancreatitis | 85 |
clinically significant | 85 |
cancer treatment | 85 |
phase i | 85 |
total number | 85 |
gastroesophageal reflux | 85 |
normal range | 85 |
high levels | 85 |
signs include | 85 |
reactive oxygen | 85 |
hospital mortality | 85 |
significant correlation | 84 |
primary outcome | 84 |
patients suffering | 84 |
hiv infection | 84 |
prognostic factors | 84 |
prick test | 84 |
may increase | 84 |
common causes | 84 |
oxygen saturation | 84 |
radical prostatectomy | 84 |
animal model | 84 |
eff ect | 83 |
drug administration | 83 |
time points | 83 |
internal medicine | 83 |
bowel obstruction | 83 |
blunt trauma | 83 |
chronic obstructive | 83 |
treatment groups | 83 |
newly diagnosed | 83 |
retrospective chart | 83 |
prick tests | 83 |
nai treatment | 83 |
treatment arms | 82 |
peritoneal dialysis | 82 |
rib fractures | 82 |
severity score | 82 |
significantly associated | 82 |
high mortality | 82 |
portal vein | 82 |
successful treatment | 82 |
injury severity | 82 |
previous studies | 82 |
less likely | 82 |
male patient | 81 |
randomised controlled | 81 |
eff ective | 81 |
grocery store | 81 |
retrospective cohort | 81 |
three times | 81 |
central venous | 81 |
drug resistance | 81 |
may present | 81 |
respiratory symptoms | 81 |
mast cells | 81 |
vena cava | 81 |
positive patients | 81 |
clinical response | 81 |
pharmaceutical care | 81 |
patients presenting | 81 |
invasive surgery | 81 |
acute abdominal | 81 |
often associated | 80 |
retrospective review | 80 |
disease activity | 80 |
icu patients | 80 |
kg body | 80 |
gastrointestinal disease | 80 |
new york | 80 |
significantly improved | 80 |
surgical management | 79 |
ige levels | 79 |
age group | 79 |
arterial pressure | 79 |
animals may | 79 |
dependent manner | 79 |
inflammatory cytokines | 79 |
results show | 79 |
resistant bacteria | 79 |
radiation dose | 79 |
high level | 79 |
apache ii | 79 |
dust mite | 79 |
two weeks | 79 |
wastewater treatment | 79 |
drug use | 78 |
sample size | 78 |
days later | 78 |
fi bers | 78 |
sleeve gastrectomy | 78 |
factor viii | 78 |
platelet aggregation | 78 |
antimicrobial therapy | 78 |
study population | 78 |
treatment period | 78 |
whenever possible | 78 |
cell culture | 78 |
supplemental oxygen | 78 |
high doses | 78 |
protective effect | 77 |
serum creatinine | 77 |
care units | 77 |
nine patients | 77 |
factor xii | 77 |
three months | 77 |
diff erence | 77 |
median time | 77 |
influenza virus | 77 |
temporal bone | 77 |
hepatic failure | 77 |
also known | 77 |
may reveal | 76 |
cervical spine | 76 |
therapy may | 76 |
respiratory system | 76 |
functional outcome | 76 |
age groups | 76 |
pegylated interferon | 76 |
real time | 76 |
plasma levels | 76 |
acute phase | 76 |
disease control | 76 |
controlled study | 76 |
blood supply | 76 |
large colon | 75 |
function tests | 75 |
survival rates | 75 |
see section | 75 |
protein levels | 75 |
inflammatory mediators | 75 |
year survival | 75 |
overall mortality | 75 |
upper airway | 75 |
may need | 75 |
patients developed | 75 |
cell lymphoma | 75 |
may affect | 74 |
lower respiratory | 74 |
imaging modality | 74 |
receptor antagonist | 74 |
case history | 74 |
acute liver | 74 |
skin tests | 74 |
wild type | 74 |
female patient | 74 |
obstructive pulmonary | 74 |
standard treatment | 74 |
postoperative course | 74 |
asthma control | 74 |
systemic lupus | 74 |
surgical approach | 74 |
patients using | 73 |
secondary bacterial | 73 |
several days | 73 |
well known | 73 |
serum concentrations | 73 |
one hundred | 73 |
innate immune | 73 |
adjuvant chemotherapy | 73 |
positive correlation | 73 |
one month | 73 |
medication adherence | 73 |
bronchial asthma | 72 |
blood cultures | 72 |
may appear | 72 |
clinical efficacy | 72 |
therapeutic effects | 72 |
human beings | 72 |
sodium bicarbonate | 72 |
good results | 72 |
serum samples | 72 |
mouse model | 72 |
disease severity | 72 |
protease inhibitors | 72 |
evaluated using | 72 |
study shows | 72 |
clinical use | 72 |
brain injury | 72 |
risk patients | 72 |
clinical outcome | 72 |
months later | 72 |
clinical history | 72 |
low dose | 72 |
open surgery | 71 |
ct scans | 71 |
postoperative pain | 71 |
skeletal muscle | 71 |
first case | 71 |
oxygen therapy | 71 |
frequently used | 71 |
chronic disease | 71 |
findings suggest | 71 |
reperfusion injury | 71 |
pleural space | 71 |
allergic diseases | 71 |
type iii | 71 |
year follow | 71 |
median follow | 71 |
incubation period | 71 |
node dissection | 71 |
low risk | 71 |
line treatment | 71 |
surface area | 71 |
one must | 71 |
united kingdom | 70 |
diagnostic tests | 70 |
laboratory tests | 70 |
safety profile | 70 |
key role | 70 |
presentation will | 70 |
acute lymphoblastic | 70 |
years ago | 70 |
nk cells | 70 |
also used | 70 |
common cold | 70 |
response rate | 70 |
specific treatment | 70 |
skin test | 69 |
first step | 69 |
nasogastric tube | 69 |
fresh frozen | 69 |
lymphoblastic leukemia | 69 |
right side | 69 |
within minutes | 69 |
leading cause | 69 |
immune globulin | 69 |
retrospectively reviewed | 69 |
effective rate | 69 |
pulmonary embolism | 69 |
lung diseases | 69 |
branch retinal | 69 |
side effect | 69 |
data collection | 69 |
tumor size | 69 |
scoring system | 69 |
associated pneumonia | 69 |
developed countries | 69 |
healthy subjects | 69 |
pseudomonas aeruginosa | 69 |
airway inflammation | 68 |
risk assessment | 68 |
liver tissue | 68 |
within months | 68 |
income countries | 68 |
also occur | 68 |
small number | 68 |
effi cacy | 68 |
rna polymerase | 68 |
gastric emptying | 68 |
will help | 68 |
drug treatment | 68 |
drug development | 68 |
severe disease | 68 |
high prevalence | 68 |
oxygen species | 68 |
month follow | 68 |
spectrum antibiotics | 68 |
grade iii | 68 |
mean time | 68 |
enzyme activity | 68 |
underwent laparoscopic | 68 |
hbv infection | 68 |
placebo group | 68 |
healthy volunteers | 68 |
clinical study | 68 |
adverse drug | 68 |
exclusion criteria | 67 |
left side | 67 |
medical university | 67 |
smoking cessation | 67 |
patient safety | 67 |
patients will | 67 |
defi ned | 67 |
first year | 67 |
lipid peroxidation | 67 |
soft palate | 67 |
naturally occurring | 67 |
recent study | 67 |
multidisciplinary team | 67 |
treatment planning | 67 |
acute abdomen | 67 |
phase iii | 67 |
portal hypertension | 67 |
broad spectrum | 67 |
three different | 67 |
tissue damage | 67 |
medical therapy | 67 |
inflammatory diseases | 67 |
propensity score | 66 |
indocyanine green | 66 |
successfully treated | 66 |
aged years | 66 |
opioid use | 66 |
small animal | 66 |
male patients | 66 |
assessed using | 66 |
also found | 66 |
diagnostic accuracy | 66 |
cardiac arrest | 66 |
intravascular coagulation | 66 |
kg min | 66 |
adult horses | 66 |
whole body | 66 |
renal dysfunction | 66 |
clinical management | 66 |
appropriate treatment | 66 |
mesenchymal stem | 66 |
clinical relevance | 65 |
patient population | 65 |
positive results | 65 |
therapeutic options | 65 |
asthma exacerbations | 65 |
treatment failure | 65 |
bacterial pneumonia | 65 |
bladder cancer | 65 |
negative pressure | 65 |
peritoneal cavity | 65 |
chest pain | 65 |
new treatment | 65 |
infection may | 65 |
blood vessels | 65 |
practice guidelines | 65 |
skin lesions | 65 |
first hours | 65 |
laboratory data | 65 |
viral hepatitis | 64 |
traditional chinese | 64 |
clostridium difficile | 64 |
mechanically ventilated | 64 |
related complications | 64 |
data collected | 64 |
patient developed | 64 |
kg per | 64 |
wound infection | 64 |
investigation results | 64 |
recurrence rate | 64 |
demographic data | 64 |
bariatric surgery | 64 |
serum hbv | 64 |
currently available | 64 |
showed significant | 64 |
renal disease | 64 |
signs may | 64 |
group compared | 64 |
patient outcomes | 64 |
carbon dioxide | 64 |
medical care | 64 |
chest tube | 64 |
asthma symptoms | 64 |
guinea pigs | 64 |
chronic liver | 64 |
interferon alfa | 63 |
therapeutic strategies | 63 |
systemic inflammation | 63 |
unified protocol | 63 |
cancer therapy | 63 |
brachial plexus | 63 |
kidney disease | 63 |
autoimmune diseases | 63 |
term results | 63 |
disseminated intravascular | 63 |
fi ndings | 63 |
anastomotic leak | 63 |
vital signs | 63 |
ischemic colitis | 63 |
antiviral treatment | 63 |
linear regression | 63 |
cell lung | 63 |
ms ms | 63 |
inflammatory disease | 63 |
expression level | 63 |
dendritic cells | 62 |
pain management | 62 |
esophageal sphincter | 62 |
life cycle | 62 |
previously reported | 62 |
determined using | 62 |
fecal samples | 62 |
single center | 62 |
internal fixation | 62 |
two months | 62 |
cell surface | 62 |
frozen plasma | 62 |
pediatric oncology | 62 |
made available | 62 |
nasal spray | 62 |
liquid chromatography | 62 |
related problems | 62 |
intestinal tract | 62 |
hepatic lipidosis | 62 |
higher incidence | 62 |
total effective | 61 |
early detection | 61 |
dose intravenous | 61 |
nucleic acid | 61 |
children aged | 61 |
early stages | 61 |
study aims | 61 |
log copies | 61 |
peginterferon alfa | 61 |
major cause | 61 |
high incidence | 61 |
nasal cavity | 61 |
hcv rna | 61 |
chronic inflammatory | 61 |
teaching hospital | 61 |
cardiovascular disease | 61 |
cant diff | 61 |
chest wall | 61 |
significant changes | 61 |
transplant recipients | 61 |
clinical examination | 61 |
combination treatment | 61 |
control study | 61 |
infl ammation | 61 |
odds ratio | 61 |
skin testing | 61 |
cystic fibrosis | 61 |
gi tract | 60 |
operating room | 60 |
trauma care | 60 |
soft tissues | 60 |
fl ow | 60 |
young adults | 60 |
molecular mechanisms | 60 |
minimal invasive | 60 |
cell membrane | 60 |
partial nephrectomy | 60 |
hypersensitivity reactions | 60 |
outer ring | 60 |
diagnostic imaging | 60 |
therapeutic effect | 60 |
platelet counts | 60 |
red cells | 60 |
iron deficiency | 60 |
term outcomes | 60 |
serum albumin | 60 |
medical management | 60 |
head injury | 60 |
therapeutic efficacy | 59 |
also observed | 59 |
three days | 59 |
extremely rare | 59 |
one third | 59 |
ten patients | 59 |
parenteral nutrition | 59 |
gas exchange | 59 |
intravenous fluid | 59 |
may reduce | 59 |
macular edema | 59 |
female patients | 59 |
toxic effects | 59 |
precision medicine | 59 |
common clinical | 59 |
von willebrand | 59 |
studies showed | 59 |
randomly divided | 59 |
viral replication | 59 |
nasal congestion | 59 |
first week | 59 |
rectal prolapse | 59 |
symptom score | 59 |
open reduction | 59 |
diagnostic criteria | 59 |
abdominal surgery | 59 |
short term | 59 |
diffi cult | 59 |
significant relationships | 58 |
independent risk | 58 |
wide variety | 58 |
patient died | 58 |
chronic inflammation | 58 |
antiviral therapy | 58 |
significant association | 58 |
cell transplant | 58 |
nutritional support | 58 |
conversion rate | 58 |
surgical excision | 58 |
background aims | 58 |
atrial fibrillation | 58 |
supine position | 58 |
increased significantly | 58 |
fatty liver | 58 |
another study | 58 |
disease process | 58 |
group received | 58 |
clinical experience | 58 |
will discuss | 58 |
endotracheal tube | 57 |
mycoplasma pneumoniae | 57 |
patients reported | 57 |
four groups | 57 |
fat diet | 57 |
animal experiments | 57 |
mean arterial | 57 |
immunoglobulin therapy | 57 |
univariate analysis | 57 |
first line | 57 |
radiation exposure | 57 |
future studies | 57 |
patients required | 57 |
ace inhibitors | 57 |
surgical correction | 57 |
diabetic patients | 57 |
randomly assigned | 57 |
every weeks | 57 |
antiviral drugs | 57 |
data analysis | 57 |
severe respiratory | 57 |
upper gi | 57 |
treatment strategies | 57 |
blood volume | 57 |
realized treatment | 57 |
cardiac function | 57 |
liver enzymes | 57 |
solid tumors | 56 |
invasive approach | 56 |
national health | 56 |
based treatment | 56 |
mononuclear cells | 56 |
antibiotic resistance | 56 |
coronavirus infection | 56 |
month period | 56 |
vast majority | 56 |
robotic surgery | 56 |
within normal | 56 |
control subjects | 56 |
liver resection | 56 |
oxygen delivery | 56 |
lower esophageal | 56 |
large amounts | 56 |
laboratory animal | 56 |
tyrosine kinase | 56 |
standard deviation | 56 |
cause severe | 56 |
quality control | 56 |
innate immunity | 56 |
liver diseases | 56 |
infected animals | 56 |
western blotting | 56 |
myeloid leukemia | 56 |
organ dysfunction | 56 |
past years | 56 |
clinical evaluation | 56 |
body condition | 56 |
healthcare professionals | 56 |
marrow transplantation | 55 |
potential outcomes | 55 |
inguinal hernia | 55 |
streptococcus pneumoniae | 55 |
well established | 55 |
blood transfusions | 55 |
often used | 55 |
healthy dogs | 55 |
pulmonary vascular | 55 |
lesions may | 55 |
clinical disease | 55 |
abdominal ultrasound | 55 |
protein kinase | 55 |
pediatric population | 55 |
drug reactions | 55 |
transcription factor | 55 |
abdominal ct | 55 |
mean number | 54 |
decreased significantly | 54 |
chb patients | 54 |
will provide | 54 |
cord blood | 54 |
first months | 54 |
urine output | 54 |
patients infected | 54 |
intravenous administration | 54 |
tissue samples | 54 |
patients taking | 54 |
healthy individuals | 54 |
high rate | 54 |
birth weight | 54 |
cd cells | 54 |
weight gain | 54 |
community pharmacy | 54 |
birth defects | 54 |
myasthenia gravis | 54 |
low molecular | 54 |
complete response | 54 |
signaling pathways | 54 |
cranial base | 54 |
pleural effusions | 54 |
beneficial effects | 54 |
months post | 53 |
gastric ulcers | 53 |
low levels | 53 |
kg times | 53 |
major complications | 53 |
infectious agents | 53 |
north america | 53 |
community pharmacies | 53 |
vascular resistance | 53 |
kg orally | 53 |
liver metastases | 53 |
large bowel | 53 |
acute myocardial | 53 |
antiviral agents | 53 |
blood culture | 53 |
therapeutic agents | 53 |
remaining patients | 53 |
colorectal surgery | 53 |
potential therapeutic | 53 |
allergic asthma | 53 |
differentially expressed | 53 |
may benefit | 53 |
high concentrations | 53 |
acute chest | 53 |
obese patients | 53 |
adverse event | 53 |
total body | 53 |
family members | 53 |
vascular permeability | 53 |
fungal infections | 53 |
persistent asthma | 53 |
ethylene glycol | 52 |
evidence suggests | 52 |
infl uence | 52 |
prospective studies | 52 |
symptom onset | 52 |
following treatment | 52 |
will need | 52 |
antiretroviral therapy | 52 |
copd patients | 52 |
vascular endothelial | 52 |
diaphragmatic hernia | 52 |
contrast agents | 52 |
grocery stores | 52 |
patients requiring | 52 |
diff erences | 52 |
oncology patients | 52 |
herpes simplex | 52 |
blood products | 52 |
radiofrequency ablation | 52 |
cell growth | 52 |
treatment outcomes | 52 |
electrolyte abnormalities | 52 |
treatment modalities | 52 |
use disorder | 52 |
electron microscopy | 52 |
nasal discharge | 52 |
chest ct | 52 |
early treatment | 52 |
fl uid | 52 |
systemic inflammatory | 52 |
urinary bladder | 52 |
beneficial effect | 52 |
ultrasound examination | 52 |
times daily | 52 |
interventional radiology | 52 |
pathologic findings | 52 |
tissue perfusion | 52 |
diagnostic tool | 52 |
reflux disease | 52 |
better understand | 52 |
cirrhotic patients | 51 |
chinese medicine | 51 |
operative complications | 51 |
much higher | 51 |
examination revealed | 51 |
laboratory animals | 51 |
head trauma | 51 |
average time | 51 |
baseline characteristics | 51 |
gel electrophoresis | 51 |
inhaled corticosteroids | 51 |
physical activity | 51 |
controlled clinical | 51 |
metabolic syndrome | 51 |
time period | 51 |
neutropenic patients | 51 |
per week | 51 |
nonsteroidal antiinflammatory | 51 |
specific igg | 51 |
group iii | 51 |
gestational age | 51 |
human monoclonal | 51 |
chest radiograph | 51 |
clinical pharmacists | 51 |
age range | 51 |
patients included | 51 |
acute myeloid | 51 |
liver fibrosis | 51 |
local recurrence | 51 |
patient characteristics | 51 |
average treatment | 51 |
animals will | 51 |
hiatal hernia | 51 |
negative bacteria | 51 |
interstitial lung | 51 |
patients whose | 51 |
among children | 50 |
several weeks | 50 |
nasal obstruction | 50 |
intravenous injection | 50 |
dna levels | 50 |
immunosorbent assay | 50 |
regression model | 50 |
wall thickness | 50 |
adhesion molecules | 50 |
lactate levels | 50 |
time point | 50 |
national institute | 50 |
general hospital | 50 |
examination findings | 50 |
mean duration | 50 |
confidence interval | 50 |
blot analysis | 50 |
use disorders | 50 |
treated conservatively | 50 |
temporal bones | 50 |
alkaline phosphatase | 50 |
jugular vein | 50 |
health status | 50 |
coronavirus pneumonia | 50 |
immune cells | 50 |
pulmonary tuberculosis | 50 |
inflammatory drugs | 50 |
patient management | 50 |
trauma registry | 49 |
social media | 49 |
clinical significance | 49 |
endemic areas | 49 |
large numbers | 49 |
childhood cancer | 49 |
allergic reaction | 49 |
airway pressure | 49 |
sectional study | 49 |
studies suggest | 49 |
statistically signifi | 49 |
large intestinal | 49 |
operative treatment | 49 |
last decade | 49 |
lower urinary | 49 |
loading dose | 49 |
taken together | 49 |
tidal volume | 49 |
anastomotic leakage | 49 |
hepatic encephalopathy | 49 |
radial head | 49 |
may show | 49 |
severely injured | 49 |
tumour response | 49 |
negative predictive | 49 |
potential risk | 49 |
pao fio | 49 |
study design | 49 |
treatment consists | 49 |
blood gases | 49 |
passive transfer | 49 |
antibody therapy | 49 |
study reported | 49 |
readily available | 49 |
major role | 49 |
extracellular matrix | 49 |
high morbidity | 49 |
may improve | 49 |
also showed | 49 |
retrospectively analyzed | 48 |
blood tests | 48 |
gastric ulceration | 48 |
crucial role | 48 |
higher levels | 48 |
acute lung | 48 |
three cases | 48 |
inflammatory markers | 48 |
intestinal wall | 48 |
positive control | 48 |
food allergens | 48 |
acei arbs | 48 |
cell counts | 48 |
may produce | 48 |
first days | 48 |
upper thoracic | 48 |
recommendation iia | 48 |
iron overload | 48 |
will present | 48 |
inflammatory cells | 48 |
last months | 48 |
peptic ulcer | 48 |
incisional hernia | 48 |
causative agent | 48 |
induce emesis | 48 |
growth factors | 48 |
patients hospitalized | 48 |
previously described | 48 |
surgical techniques | 48 |
receptor antagonists | 48 |
free radical | 48 |
bei der | 48 |
first choice | 48 |
clinical condition | 48 |
often present | 48 |
preliminary data | 48 |
postoperative morbidity | 48 |
lower extremity | 48 |
respiratory infection | 48 |
femoral neck | 48 |
hodgkin lymphoma | 48 |
results demonstrate | 48 |
cerebral edema | 48 |
first group | 48 |
significantly less | 48 |
survival time | 48 |
study will | 48 |
treatment duration | 47 |
external fixation | 47 |
patient group | 47 |
saline solution | 47 |
immunocompromised patients | 47 |
first day | 47 |
imaging studies | 47 |
several factors | 47 |
physical exam | 47 |
upper gastrointestinal | 47 |
functional imaging | 47 |
drug repurposing | 47 |
cov infection | 47 |
intestinal mucosa | 47 |
weighted imaging | 47 |
passive immunity | 47 |
patient received | 47 |
respiratory infectious | 47 |
higher doses | 47 |
lactic acidosis | 47 |
compartment syndrome | 47 |
molecular imaging | 47 |
several months | 47 |
life threatening | 47 |
diff erent | 47 |
serious complications | 47 |
clinical results | 47 |
proton pump | 47 |
right hemicolectomy | 47 |
protease inhibitor | 47 |
frontal bone | 47 |
mg daily | 47 |
severe head | 47 |
second group | 47 |
bite wounds | 47 |
randomized study | 47 |
substance abuse | 47 |
icu stay | 47 |
therapeutic option | 47 |
host disease | 46 |
similar results | 46 |
operating time | 46 |
virus disease | 46 |
cardiogenic shock | 46 |
medical record | 46 |
treatment strategy | 46 |
promising results | 46 |
food allergies | 46 |
treatment guidelines | 46 |
venous blood | 46 |
mucous membrane | 46 |
hcv infection | 46 |
hbeag negative | 46 |
commonly seen | 46 |
significantly better | 46 |
prone position | 46 |
systolic blood | 46 |
conventional treatment | 46 |
serious adverse | 46 |
asthmatic patients | 46 |
ascending colon | 46 |
better understanding | 46 |
american college | 46 |
superoxide dismutase | 46 |
increased levels | 46 |
lung tissue | 46 |
cardiac disease | 46 |
cell types | 46 |
data show | 46 |
least months | 46 |
may indicate | 46 |
signaling pathway | 46 |
high fat | 46 |
many years | 46 |
surg endosc | 46 |
image quality | 46 |
severe sepsis | 46 |
clostridium perfringens | 45 |
viral rna | 45 |
ejection fraction | 45 |
vein thrombosis | 45 |
drugs used | 45 |
biopsy samples | 45 |
granted medrxiv | 45 |
juvenile idiopathic | 45 |
ulcer disease | 45 |
confi rmed | 45 |
candidate locations | 45 |
compound danshen | 45 |
crystalloid fluids | 45 |
splenic injury | 45 |
clinical applications | 45 |
like symptoms | 45 |
nuclear medicine | 45 |
plasma protein | 45 |
adipose tissue | 45 |
th ese | 45 |
chronic bronchitis | 45 |
barrier function | 45 |
intervention group | 45 |
emergency medical | 45 |
chest syndrome | 45 |
information regarding | 45 |
fl exion | 45 |
conducted using | 45 |
chronic kidney | 45 |
working group | 45 |
transcription factors | 45 |
animal studies | 45 |
mean operative | 45 |
also cause | 45 |
serum total | 45 |
hospital discharge | 45 |
contact dermatitis | 45 |
among others | 45 |
endothelial cell | 45 |
less frequently | 45 |
drug susceptibility | 45 |
comparative study | 45 |
author funder | 45 |
icu admission | 45 |
protein concentration | 44 |
surgical removal | 44 |
refl ex | 44 |
drug discovery | 44 |
treated group | 44 |
traumatic brain | 44 |
high grade | 44 |
quality improvement | 44 |
neutrophil count | 44 |
standard therapy | 44 |
statistical difference | 44 |
inhibitor deficiency | 44 |
spatial treatments | 44 |
accurate diagnosis | 44 |
treatment plants | 44 |
medication use | 44 |
primary endpoint | 44 |
serum alt | 44 |
oral mucosa | 44 |
younger patients | 44 |
renal insufficiency | 44 |
clinical benefit | 44 |
vascular access | 44 |
sore throat | 44 |
early postoperative | 44 |
older children | 44 |
back pain | 44 |
urine samples | 44 |
four cases | 44 |
imaging technique | 44 |
will review | 44 |
linked immunosorbent | 44 |
two drugs | 44 |
remains unclear | 44 |
right upper | 44 |
perform orogastric | 44 |
experimental study | 44 |
old boy | 44 |
ct imaging | 44 |
old patient | 44 |
medical imaging | 44 |
will require | 44 |
care providers | 44 |
mean hospital | 44 |
kidney injury | 44 |
also important | 44 |
chronic urticaria | 44 |
least two | 44 |
treatment protocol | 44 |
cytotoxic effects | 43 |
infl ammatory | 43 |
endotracheal intubation | 43 |
intravenous immunoglobulins | 43 |
analysis using | 43 |
significant risk | 43 |
copyright holder | 43 |
daily dose | 43 |
biochemical parameters | 43 |
older patients | 43 |
patient age | 43 |
surgical interventions | 43 |
new approach | 43 |
class ii | 43 |
cytokine release | 43 |
study demonstrated | 43 |
refl ux | 43 |
inflammatory responses | 43 |
secondary outcomes | 43 |
esterase inhibitor | 43 |
fl exible | 43 |
idiopathic arthritis | 43 |
european countries | 43 |
will increase | 43 |
artificial intelligence | 43 |
new therapeutic | 43 |
scan showed | 43 |
study suggests | 43 |
plasma membrane | 43 |
renal cell | 43 |
long time | 43 |
negative correlation | 43 |
emergency care | 43 |
investigate whether | 43 |
treatment regimens | 43 |
mental status | 43 |
complications occurred | 43 |
selected cases | 43 |
paranasal sinuses | 43 |
tympanic membrane | 43 |
coagulation factors | 43 |
daily practice | 43 |
intramedullary nailing | 43 |
less invasive | 43 |
administer intravenous | 43 |
injured patients | 43 |
pregnancy registry | 43 |
right ventricular | 43 |
relatively low | 43 |
health problem | 43 |
four different | 43 |
fold increase | 43 |
kg hour | 43 |
clinical case | 43 |
based therapies | 43 |
elevated serum | 43 |
significant effect | 43 |
stage ii | 43 |
bronchoalveolar lavage | 43 |
plus ribavirin | 43 |
needle aspiration | 43 |
exploratory laparotomy | 43 |
clinical impact | 43 |
adverse effect | 43 |
carotid artery | 42 |
positive cells | 42 |
may induce | 42 |
antiviral drug | 42 |
hypovolemic shock | 42 |
clinical decision | 42 |
liver dysfunction | 42 |
binding protein | 42 |
one side | 42 |
ct angiography | 42 |
high quality | 42 |
days post | 42 |
receptor blockers | 42 |
peanut allergy | 42 |
complication rates | 42 |
protein level | 42 |
highly effective | 42 |
natural history | 42 |
three years | 42 |
different levels | 42 |
day mortality | 42 |
high frequency | 42 |
also performed | 42 |
version posted | 42 |
ovarian cancer | 42 |
many studies | 42 |
mucosal injury | 42 |
respiratory diseases | 42 |
vitro studies | 42 |
acute onset | 42 |
mustela putorius | 42 |
hemodynamically stable | 42 |
group showed | 42 |
gastric mucosa | 42 |
term outcome | 42 |
treatment regimen | 42 |
least days | 42 |
small molecule | 42 |
health professionals | 42 |
closely related | 42 |
prognostic value | 42 |
congenital heart | 42 |
chronic pancreatitis | 42 |
many different | 42 |
urinary incontinence | 42 |
hydrogen peroxide | 42 |
platelet function | 42 |
usually occurs | 42 |
veterinary medicine | 42 |
absorbed dose | 42 |
direct contact | 42 |
asthma exacerbation | 42 |
median survival | 42 |
results obtained | 42 |
identify patients | 42 |
abdominal discomfort | 42 |
signs associated | 42 |
renal impairment | 42 |
factor receptor | 42 |
maintenance treatment | 41 |
rhodococcus equi | 41 |
clinical conditions | 41 |
one patients | 41 |
inhibitory effect | 41 |
serum level | 41 |
protein synthesis | 41 |
surgical patients | 41 |
cell adhesion | 41 |
correct diagnosis | 41 |
erectile dysfunction | 41 |
diagnosis may | 41 |
data regarding | 41 |
potential role | 41 |
positive predictive | 41 |
antimicrobial activity | 41 |
passive immunization | 41 |
gland disease | 41 |
enzyme activities | 41 |
hbeag positive | 41 |
chronic hbv | 41 |
may predispose | 41 |
neonatal foals | 41 |
local anesthetic | 41 |
visual analogue | 41 |
tissue injury | 41 |
prothrombin time | 41 |
primary treatment | 41 |
gauge needle | 41 |
thrombocytopenic purpura | 41 |
made based | 41 |
bighorn sheep | 41 |
will often | 41 |
artery disease | 41 |
antibody titers | 41 |
every day | 41 |
grade iv | 41 |
common bile | 41 |
published data | 41 |
liver damage | 41 |
serum ige | 41 |
host immune | 41 |
clinical evidence | 41 |
angioedema attacks | 41 |
operative day | 41 |
danshen injection | 41 |
will allow | 41 |
hepatic fibrosis | 41 |
one hour | 41 |
collected data | 41 |
mitral valve | 41 |
biliary tract | 41 |
fold higher | 41 |
hyoid bone | 41 |
lactic acid | 41 |
stage iii | 41 |
medical students | 41 |
calcium channel | 41 |
consecutive days | 41 |
term survival | 41 |
without complications | 41 |
medical staff | 41 |
patients experienced | 41 |
also present | 41 |
dose reduction | 41 |
asthma severity | 41 |
older age | 41 |
valve replacement | 41 |
antimicrobial agents | 41 |
study demonstrates | 40 |
hip fracture | 40 |
without evidence | 40 |
treatment room | 40 |
nk cell | 40 |
histological examination | 40 |
day course | 40 |
affected foals | 40 |
transverse colon | 40 |
glucose levels | 40 |
negative patients | 40 |
close monitoring | 40 |
respiratory function | 40 |
liver cancer | 40 |
high sensitivity | 40 |
normal serum | 40 |
protein binding | 40 |
dose dependent | 40 |
specific antibody | 40 |
corticosteroid therapy | 40 |
thoracic trauma | 40 |
th postoperative | 40 |
femoral head | 40 |
asthmatic children | 40 |
milk allergy | 40 |
higher rate | 40 |
positive skin | 40 |
identifi cation | 40 |
potential treatment | 40 |
bacterial pathogens | 40 |
immune function | 40 |
compared using | 40 |
cardiac index | 40 |
functional outcomes | 40 |
multicenter study | 40 |
pain control | 40 |
hemorrhagic shock | 40 |
useful tool | 40 |
sectional imaging | 40 |
stage i | 40 |
dose activated | 40 |
ace inhibitor | 40 |
physical therapy | 40 |
took place | 40 |
million people | 40 |
cytokine production | 40 |
infectious complications | 40 |
organ systems | 40 |
associated injuries | 40 |
general condition | 40 |
viral clearance | 40 |
clinical setting | 40 |
key point | 40 |
flunixin meglumine | 40 |
hbeag seroconversion | 40 |
effective method | 40 |
alanine aminotransferase | 40 |
healthy control | 40 |
observational studies | 40 |
invasive treatment | 40 |
four times | 40 |
community pharmacists | 40 |
lyme disease | 40 |
mrna levels | 40 |
gastric lavage | 40 |
randomized trials | 40 |
commonly found | 40 |
international license | 40 |
aortic arch | 40 |
data indicate | 40 |
without treatment | 39 |
vascular injury | 39 |
plasma concentration | 39 |
complete resolution | 39 |
linear foreign | 39 |
american society | 39 |
relatively high | 39 |
orally administered | 39 |
glucose tolerance | 39 |
rotator cuff | 39 |
grade i | 39 |
targeted therapy | 39 |
will show | 39 |
skin scrapings | 39 |
disease caused | 39 |
treatment modality | 39 |
compassionate use | 39 |
significant morbidity | 39 |
times higher | 39 |
several times | 39 |
ii score | 39 |
antibiotic prophylaxis | 39 |
every days | 39 |
post operative | 39 |
first two | 39 |
relative risk | 39 |
pancreatic cancer | 39 |
natural killer | 39 |
gamma globulin | 39 |
mammary gland | 39 |
data obtained | 39 |
calculated using | 39 |
barr virus | 39 |
sbt abpc | 39 |
environmental factors | 39 |
urinary catheter | 39 |
well documented | 39 |
acute otitis | 39 |
study using | 39 |
experimental studies | 39 |
research setting | 39 |
surgical site | 39 |
nasal cavities | 39 |
blood donors | 39 |
oral antibiotics | 39 |
additional information | 39 |
total score | 39 |
free radicals | 39 |
putorius furo | 39 |
sigmoid colon | 39 |
critical role | 39 |
venous pressure | 39 |
gleason score | 39 |
molecular biology | 39 |
underwent surgery | 39 |
patient satisfaction | 39 |
clinical information | 39 |
major trauma | 39 |
clinically normal | 39 |
ulcerative colitis | 39 |
host cells | 39 |
cell survival | 39 |
cell cultures | 39 |
adverse reaction | 39 |
cases showed | 39 |
may prevent | 39 |
cancer surgery | 39 |
mean length | 39 |
severe trauma | 39 |
thoracic society | 39 |
antiinflammatory drugs | 39 |
may serve | 39 |
world studies | 39 |
mucosal barrier | 39 |
left atrial | 39 |
may represent | 39 |
new drug | 39 |
square test | 39 |
may involve | 39 |
rank test | 39 |
findings may | 39 |
two days | 39 |
epithelial cell | 39 |
outpatient clinic | 39 |
angiotensin ii | 39 |
affected dogs | 38 |
significantly greater | 38 |
treatment will | 38 |
ige level | 38 |
patienten mit | 38 |
bile acids | 38 |
femoral artery | 38 |
serum therapy | 38 |
patients suffered | 38 |
wound closure | 38 |
per month | 38 |
targeted therapies | 38 |
lower extremities | 38 |
neutralizing antibodies | 38 |
hcc patients | 38 |
ear canal | 38 |
hereditary angioneurotic | 38 |
related adverse | 38 |
will lead | 38 |
occur within | 38 |
ex vivo | 38 |
childhood asthma | 38 |
pulse oximetry | 38 |
varying degrees | 38 |
endothelial growth | 38 |
i will | 38 |
dna level | 38 |
complete remission | 38 |
one course | 38 |
make sure | 38 |
thoracic spine | 38 |
term treatment | 38 |
septic peritonitis | 38 |
locally advanced | 38 |
umbilical cord | 38 |
next generation | 38 |
recombinant human | 38 |
imaging methods | 38 |
upper extremity | 38 |
nasal mucosa | 38 |
therapeutic approach | 38 |
steady state | 38 |
mesenteric artery | 38 |
cell aplasia | 38 |
mean values | 38 |
sexual selection | 38 |
significant impact | 38 |
symptomatic patients | 38 |
pharmaceutical interventions | 38 |
penetrating trauma | 38 |
good clinical | 38 |
spontaneous pneumothorax | 38 |
oxygen consumption | 38 |
per os | 38 |
pelvic fractures | 38 |
high resolution | 38 |
genomic dna | 38 |
female ratio | 38 |
acute kidney | 38 |
individual patient | 37 |
high degree | 37 |
specific antibodies | 37 |
internal rotation | 37 |
significant role | 37 |
sos vod | 37 |
important factor | 37 |
health problems | 37 |
prospective cohort | 37 |
limited number | 37 |
young patients | 37 |
ferrets may | 37 |
external rotation | 37 |
weeks later | 37 |
biomedical research | 37 |
acute cholecystitis | 37 |
active metabolite | 37 |
two types | 37 |
lymphocyte count | 37 |
patient groups | 37 |
therapeutic approaches | 37 |
laparoscopic repair | 37 |
seasonal allergic | 37 |
intercostal space | 37 |
sleep apnea | 37 |
small amounts | 37 |
auf die | 37 |
health outcomes | 37 |
low level | 37 |
frequently associated | 37 |
small amount | 37 |
definitive treatment | 37 |
signal transduction | 37 |
clotting factors | 37 |
observation period | 37 |
microscopic examination | 37 |
operative management | 37 |
complement activation | 37 |
peer review | 37 |
negative control | 37 |
clinical sign | 37 |
two studies | 37 |
high affinity | 37 |
chronic diseases | 37 |
unknown etiology | 37 |
bile ducts | 37 |
groups according | 37 |
intracranial pressure | 37 |
nursing home | 37 |
cardiovascular diseases | 37 |
damage control | 37 |
may decrease | 37 |
fracture healing | 37 |
old girl | 37 |
cord injury | 37 |
lactate dehydrogenase | 37 |
dawley rats | 37 |
without clinical | 37 |
protective effects | 37 |
venous thrombosis | 37 |
clinical cases | 37 |
weight bearing | 37 |
kg minute | 37 |
left lateral | 37 |
host cell | 37 |
rat model | 37 |
iu kg | 37 |
laboratory parameters | 37 |
pelvic floor | 37 |
serum concentration | 37 |
early phase | 37 |
patients operated | 37 |
discharged home | 37 |
normal values | 37 |
symptoms may | 37 |
may vary | 37 |
severe complications | 37 |
biological activity | 37 |
anaerobic bacteria | 37 |
hours later | 37 |
serum ferritin | 37 |
supportive therapy | 36 |
data will | 36 |
significantly shorter | 36 |
venous thromboembolism | 36 |
pump inhibitors | 36 |
right heart | 36 |
significantly correlated | 36 |
treatment course | 36 |
radical cystectomy | 36 |
continuous infusion | 36 |
cell volume | 36 |
virologic response | 36 |
fluorescence imaging | 36 |
diseases society | 36 |
total gastrectomy | 36 |
dna repair | 36 |
study conducted | 36 |
pain relief | 36 |
flow rate | 36 |
clinical research | 36 |
nh gene | 36 |
per rectum | 36 |
special attention | 36 |
four weeks | 36 |
predictive factors | 36 |
trauma team | 36 |
thoracic radiographs | 36 |
surgical drainage | 36 |
capillary refill | 36 |
studies indicate | 36 |
drug related | 36 |
empiric therapy | 36 |
assess whether | 36 |
grade ii | 36 |
poor outcome | 36 |
mg every | 36 |
mesenteric lymph | 36 |
dust mites | 36 |
line therapy | 36 |
chronic renal | 36 |
estimated blood | 36 |
neuraminidase inhibitors | 36 |
solid organ | 36 |
facial nerve | 36 |
significant higher | 36 |
treatment assignment | 36 |
septic arthritis | 36 |
nissen fundoplication | 36 |
surgical exploration | 36 |
tumor growth | 36 |
patients completed | 36 |
increased incidence | 36 |
superior mesenteric | 36 |
white matter | 36 |
clinical diagnosis | 36 |
factors affecting | 36 |
chemotherapeutic agents | 36 |
may explain | 36 |
perfusion imaging | 36 |
orally every | 36 |
provocation test | 36 |
international guidelines | 36 |
also associated | 36 |
percutaneous drainage | 36 |
mouth breathing | 36 |
cerebral blood | 36 |
healthy adult | 36 |
abdominal distention | 36 |
qt interval | 36 |
cell activation | 36 |
severe forms | 36 |
lecture will | 36 |
session will | 35 |
study found | 35 |
research council | 35 |
mit einem | 35 |
empirical success | 35 |
protective equipment | 35 |
increased serum | 35 |
clinical application | 35 |
cell migration | 35 |
pediatric hematology | 35 |
exact test | 35 |
proinflammatory cytokines | 35 |
birch pollen | 35 |
health system | 35 |
young animals | 35 |
diagnostic value | 35 |
metastatic breast | 35 |
active disease | 35 |
care professionals | 35 |
rare complication | 35 |
predisposing factors | 35 |
pediatric cancer | 35 |
human body | 35 |
cases may | 35 |
cell membranes | 35 |
high fever | 35 |
done using | 35 |
multidisciplinary approach | 35 |
high rates | 35 |
blood circulation | 35 |
often difficult | 35 |
urothelial carcinoma | 35 |
literature search | 35 |
epidermal growth | 35 |
nursing staff | 35 |
results will | 35 |
patient demographics | 35 |
normal saline | 35 |
clinical effects | 35 |
small colon | 35 |
short time | 35 |
therapeutic strategy | 35 |
recurrent laryngeal | 35 |
sterile saline | 35 |
autoimmune disease | 35 |
findings include | 35 |
autosomal recessive | 35 |
contrast agent | 35 |
functional results | 35 |
commonly associated | 35 |
months follow | 35 |
weight heparin | 35 |
hemorrhagic fever | 35 |
sars coronavirus | 35 |
trauma centers | 35 |
corticosteroid treatment | 35 |
five years | 35 |
gas analysis | 35 |
contrast enhancement | 35 |
five cases | 35 |
haemophilus influenzae | 35 |
infected cells | 35 |
recent advances | 35 |
dna methylation | 35 |
currently used | 35 |
contact system | 35 |
external fixator | 35 |
immunosuppressive therapy | 35 |
mainly due | 35 |
specific immunotherapy | 35 |
refill time | 35 |
intestinal disease | 35 |
antimicrobial resistance | 35 |
diagnostic laparoscopy | 35 |
laryngeal nerve | 35 |
right atrium | 35 |
abdominal distension | 35 |
icg fluorescence | 35 |
correlation coefficient | 35 |
pathological findings | 35 |
kidney transplantation | 35 |
mycobacterium tuberculosis | 35 |
mg bid | 35 |
enteric viruses | 35 |
descriptive study | 35 |
response rates | 35 |
target genes | 35 |
poorly understood | 35 |
tumor cell | 35 |
remains controversial | 34 |
near future | 34 |
septic patients | 34 |
cord compression | 34 |
usually associated | 34 |
human health | 34 |
sodium chloride | 34 |
widespread use | 34 |
must also | 34 |
clinical audit | 34 |
obstructive sleep | 34 |
coronary heart | 34 |
rare case | 34 |
dynamic contrast | 34 |
side eff | 34 |
brain death | 34 |
hemodynamic instability | 34 |
fi stula | 34 |
patient may | 34 |
new drugs | 34 |
studies reported | 34 |
signal intensity | 34 |
bacterial culture | 34 |
medical conditions | 34 |
graft placement | 34 |
fi nd | 34 |
systemic symptoms | 34 |
initial management | 34 |
positive effect | 34 |
artery bypass | 34 |
paediatric patients | 34 |
tight junction | 34 |
particular attention | 34 |
ivig may | 34 |
enteric bacteria | 34 |
using two | 34 |
distal radius | 34 |
future research | 34 |
quality assurance | 34 |
third trimester | 34 |
will include | 34 |
adrenal tumors | 34 |
mean score | 34 |
normal limits | 34 |
passive immunotherapy | 34 |
willebrand factor | 34 |
falciparum malaria | 34 |
increasing number | 34 |
wbc count | 34 |
body surface | 34 |
ethics committee | 34 |
room temperature | 34 |
hours post | 34 |
patient selection | 34 |
emergency treatment | 34 |
provide information | 34 |
spatial resolution | 34 |
neoadjuvant chemotherapy | 34 |
blunt abdominal | 34 |
partial response | 34 |
improve patient | 34 |
endoscopic surgery | 34 |
otherwise healthy | 34 |
intravenous crystalloid | 34 |
surgical therapy | 34 |
surgical repair | 34 |
high serum | 34 |
health service | 34 |
second patient | 34 |
elevated levels | 34 |
intravenous infusion | 34 |
surgical emergency | 34 |
signifi cance | 34 |
infections may | 34 |
renal transplant | 34 |
treatment efficacy | 34 |
early recognition | 34 |
infections caused | 34 |
within weeks | 34 |
ct images | 34 |
hae attacks | 34 |
will continue | 34 |
eligible patients | 34 |
cells mm | 34 |
trimester exposure | 34 |
hcc cell | 34 |
two thirds | 34 |
electronic medical | 34 |
tube placement | 34 |
tranexamic acid | 34 |
also reported | 33 |
granulation tissue | 33 |
depressive disorder | 33 |
significant change | 33 |
cancer stem | 33 |
imaging features | 33 |
viral pneumonia | 33 |
will develop | 33 |
term use | 33 |
administered orally | 33 |
takes place | 33 |
current treatment | 33 |
new coronavirus | 33 |
conventional therapy | 33 |
oxide synthase | 33 |
analysed using | 33 |
egg white | 33 |
treatment results | 33 |
small molecules | 33 |
treatment suspensions | 33 |
different doses | 33 |
resistant strains | 33 |
rural areas | 33 |
muscle cells | 33 |
necrotizing fasciitis | 33 |
outcome measure | 33 |
better results | 33 |
studies will | 33 |
delayed diagnosis | 33 |
enteral nutrition | 33 |
flaxseed oil | 33 |
organ injury | 33 |
within one | 33 |
revision surgery | 33 |
american academy | 33 |
drug delivery | 33 |
dose adjustment | 33 |
intravenous catheter | 33 |
pain score | 33 |
presumptive diagnosis | 33 |
average number | 33 |
adjuvant therapy | 33 |
reference range | 33 |
gastric contents | 33 |
transit time | 33 |
drugs may | 33 |
susceptibility testing | 33 |
prognostic factor | 33 |
reported cases | 33 |
asthma patients | 33 |
abdominal organs | 33 |
psychiatric disorders | 33 |
laryngeal edema | 33 |
nerve palsy | 33 |
become infected | 33 |
control measures | 33 |
negative impact | 33 |
risk groups | 33 |
important cause | 33 |
cystic duct | 33 |
valproic acid | 33 |
medical literature | 33 |
limited data | 33 |
alt levels | 33 |
bone metastases | 33 |
acute leukemia | 33 |
ml vs | 33 |
individual patients | 33 |
pathogenic bacteria | 33 |
also significantly | 33 |
chronic diarrhea | 33 |
plasma products | 33 |
arterial hypertension | 33 |
catheter placement | 33 |
erectile function | 33 |
therapeutic intervention | 33 |
anterior wall | 33 |
maintenance therapy | 33 |
macular oedema | 33 |
pleural cavity | 33 |
helicobacter pylori | 33 |
enhanced ct | 33 |
normal tissue | 33 |
well understood | 33 |
conservative management | 33 |
surgical complications | 33 |
neonatal isoerythrolysis | 33 |
less severe | 33 |
hong kong | 33 |
hepatic artery | 33 |
curative treatment | 33 |
ic values | 33 |
burn injury | 33 |
basement membrane | 33 |
antiviral effect | 33 |
results demonstrated | 33 |
human plasma | 33 |
drug allergy | 33 |
igg levels | 33 |
ige binding | 33 |
take care | 33 |
descriptive statistics | 33 |
one day | 33 |
cox regression | 33 |
splenic artery | 33 |
considered significant | 33 |
cerebrospinal fluid | 33 |
may take | 32 |
brain tissue | 32 |
expiratory flow | 32 |
diagnoses include | 32 |
skin biopsy | 32 |
gastric acid | 32 |
clinical parameters | 32 |
cells showed | 32 |
patients achieved | 32 |
renal injury | 32 |
plasma cells | 32 |
recommendation iib | 32 |
hepg cells | 32 |
cytotoxic effect | 32 |
closed reduction | 32 |
gastrointestinal symptoms | 32 |
qt prolongation | 32 |
helicobacter spp | 32 |
stent placement | 32 |
pure red | 32 |
angiotensin converting | 32 |
spectrum antiviral | 32 |
response syndrome | 32 |
inhibitory effects | 32 |
strand breaks | 32 |
almost always | 32 |
also shown | 32 |
oncological outcomes | 32 |
pollen season | 32 |
opportunistic infections | 32 |
glucose concentration | 32 |
including patients | 32 |
water reuse | 32 |
inferior vena | 32 |
organ damage | 32 |
intestinal motility | 32 |
increasingly used | 32 |
palliative care | 32 |
every months | 32 |
cardiovascular system | 32 |
patient data | 32 |
significantly elevated | 32 |
prospective randomized | 32 |
treated cells | 32 |
class i | 32 |
first patient | 32 |
antibiotic use | 32 |
last two | 32 |
retrospective case | 32 |
gastrointestinal bleeding | 32 |
controlled studies | 32 |
fibrin glue | 32 |
interstitial pneumonia | 32 |
may allow | 32 |
generation cephalosporin | 32 |
preventive measures | 32 |
label use | 32 |
treat patients | 32 |
commonly affected | 32 |
analogue scale | 32 |
fi eld | 32 |
young adult | 32 |
south africa | 32 |
retrospective observational | 32 |
hae type | 32 |
lower limb | 32 |
mediated immunity | 32 |
first weeks | 32 |
cancer survivors | 32 |
posterior wall | 32 |
plasma samples | 32 |
tertiary care | 32 |
da vinci | 32 |
antiretroviral pregnancy | 32 |
neural networks | 32 |
two hours | 32 |
factors may | 32 |
pancreatic duct | 32 |
packed red | 32 |
receiving treatment | 32 |
experimentally induced | 32 |
serum biochemical | 32 |
oncotic pressure | 32 |
infection control | 32 |
participant data | 32 |
ventilated patients | 32 |
symptomatic treatment | 32 |
aortic valve | 32 |
last year | 32 |
viral inactivation | 32 |